Patent: 5,382,524
Summary for Patent: 5,382,524
| Title: | Cloning and expression of biologically active α-n-acetylgalactosaminidase |
| Abstract: | The present invention involves the production of human alpha -GalNAc by cloning and expressing the alpha -GalNAc coding sequence in eukaryotic host cell expressions systems. The eukaryotic expression systems, and in particular the mammalian host cell expression systems described herein provide for the appropriate co-translational and post-translation modifications required or proper processing, e.g., glycosylation, phosphorylation, etc. and sorting of the expression product so that an active enzyme is produced. The alpha -GalNAc produced in accordance with the invention may be used in the treatment of Schindler disease or for the hydrolysis of alpha -N-acetylgalactosaminyl moieties in various glycoconjugates. |
| Inventor(s): | Robert J. Desnick, David F. Bishop, Yiannis A. Ioannou, Anne M. Wang |
| Assignee: | Icahn School of Medicine at Mount Sinai |
| Application Number: | US07/602,608 |
| Patent Claims: | see list of patent claims |
Details for Patent 5,382,524
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
|---|---|---|---|---|---|---|---|
| Genzyme Corporation | FABRAZYME | agalsidase beta | For Injection | 103979 | April 24, 2003 | 5,382,524 | 2012-01-17 |
| Genzyme Corporation | FABRAZYME | agalsidase beta | For Injection | 103979 | October 10, 2003 | 5,382,524 | 2012-01-17 |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
